Schering-Plough/Merck Pharmaceuticals (SPM) announced that the New Drug Application filing for loratadine/montelukast has been accepted by the U.S. Food and Drug Administration (FDA) for standard review.
Itching for a better anti-itch remedy — Your wish may soon be granted now that scientists at Washington University School of Medicine in St. Louis have identified the first gene for the itch sensation in the central nervous system.
Itching for a better anti-itch remedy” Your wish may soon be granted now that scientists at Washington University School of Medicine in St. Louis have identified the first gene for the itch sensation in the central nervous system.
Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach — usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of “The Oncologist.”
Insect stings are the cause of 500,000 emergency room visits each year, and more than two million Americans are allergic to stinging insects.
With all the extra free-time that comes with summer vacation, Temple University pediatrician Andrea McCoy offers several tips to keep children active and avoid sedentary behavior during their extended break.
Researchers at Johns Hopkins have discovered that the same ingredient used in dandruff shampoos to fight the burning, itching and flaking on your head also can calm overexcited nerve cells inside your head, making it a potential treatment for seizures. Results of the study can be found online in Nature Chemical Biology.
An anti-reflux valve developed to help esophageal cancer patients also has been shown to help those with bile duct obstruction, according to Kulwinder S. Dua, M.D., a research physician at the Medical College of Wisconsin in Milwaukee.
The U.S. Food and Drug Administration (FDA) licensed Ceprotin, the first biologic treatment for patients with a rare genetic defect that can cause a potentially life-threatening clotting disorder.
GlaxoSmithKline (GSK) announced the presentation of new data on fluticasone furoate nasal spray (FFNS), an enhanced affinity intranasal corticosteroid (INS) currently in development for use in the treatment of allergic rhinitis.